Every Form 4 that LeonaBio, Inc. (LONA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow LONA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LONA filings page.
LeonaBio, Inc. reported a Form 4 showing a grant of stock options covering 28,000 shares of common stock to a board designee associated with Perceptive Advisors. The options have an exercise price of $9.54 per share and expire on April 8, 2036, vesting monthly over 24 months while the optionee continues as a Service Provider.
LeonaBio, Inc. reported a Form 4 showing an option grant related to director compensation. Entities associated with director Joseph Edelman received a stock option covering 28,000 shares of common stock at an exercise price of $8.35 per share. The option vests on the earlier of June 23, 2027 or the day before the next annual stockholder meeting after June 22, 2026, and expires on June 22, 2036. The grant was made under LeonaBio’s Outside Director Compensation Policy, with Perceptive entities having an indirect pecuniary interest through a management fee offset and disclaiming beneficial ownership except to that extent.
LeonaBio, Inc. director Fred Callori received a grant of stock options covering 2,333 shares of common stock at an exercise price of $8.35 per share. These options vest on the earlier of June 23, 2027 or just before the next annual stockholder meeting after June 22, 2026 and expire on June 22, 2036.
LeonaBio, Inc. director Natalie C. Holles received a grant of stock options covering 2,333 shares of common stock. The options have an exercise price of $8.35 per share and are held as a direct ownership position.
According to the grant terms, these options vest on the earlier of June 23, 2027, or the day immediately before the next annual stockholder meeting that occurs after June 22, 2026. The grant was issued under LeonaBio’s Outside Director Compensation Policy and was pro-rated based on her appointment to the board on May 5, 2026. After this grant, her reported option holdings from this award total 2,333 shares and expire on June 22, 2036.
LeonaBio, Inc. director Peter B. Silverman received a grant of stock options covering 2,333 shares of common stock. The options have an exercise price of $8.35 per share and expire on June 22, 2036.
The options will vest on the earlier of June 23, 2027, or the day immediately before the next annual stockholder meeting held after June 22, 2026. The award was granted under LeonaBio’s Outside Director Compensation Policy and pro-rated based on his board appointment on May 5, 2026.
LeonaBio, Inc. director Michael A. Panzara received a grant of stock options covering 28,000 shares of common stock. The options have an exercise price of $8.35 per share and expire on June 22, 2036.
The options will vest on the earlier of June 23, 2027, or the day immediately before the next annual stockholder meeting that occurs after June 22, 2026. This is a compensation-related award rather than an open-market transaction.
LeonaBio, Inc. director Romano Kelly reported receiving a grant of stock options covering 28,000 shares of common stock. The options have an exercise price of $8.35 per share and expire on June 22, 2036.
The options will vest on the earlier of June 23, 2027, or the day immediately before the next annual stockholders’ meeting that occurs after June 22, 2026. The grant was made under LeonaBio’s Outside Director Compensation Policy and reflects equity-based compensation rather than an open-market purchase or sale.
LeonaBio, Inc. director Joseph Edelman received a grant of stock options covering 28,000 shares of common stock at an exercise price of $8.35 per share. The options expire on June 22, 2036 and vest on the earlier of June 23, 2027 or the day before the next annual stockholder meeting after June 22, 2026, under the company’s Outside Director Compensation Policy.
LeonaBio, Inc. director James A. Johnson received a grant of stock options as part of his outside director compensation. He was awarded 28,000 stock options to acquire LeonaBio common stock at an exercise price of $8.35 per share. The options vest on the earlier of June 23, 2027, or the day immediately before the next annual stockholder meeting that occurs after June 22, 2026, and expire on June 22, 2036. Following this grant, Johnson holds 28,000 options to purchase LeonaBio common stock directly.
LeonaBio, Inc. director Barbara Kosacz received a grant of stock options as part of outside director compensation. The award covers 28,000 stock options for common stock with an exercise price of $8.35 per share, expiring on June 22, 2036.
The options will vest on the earlier of June 23, 2027, or the day immediately before the next annual stockholder meeting that occurs after June 22, 2026. Following this grant, she holds 28,000 derivative securities directly.
LeonaBio director Grant Pickering received a grant of stock options for 28,000 shares of common stock. The options have an exercise price of $8.35 per share and expire on June 22, 2036. All 28,000 options were outstanding after the transaction, held as a direct position.
The options will vest on the earlier of June 23, 2027 or the day immediately before the next annual stockholder meeting that occurs after June 22, 2026. The grant was made under LeonaBio’s Outside Director Compensation Policy, indicating it is part of routine director compensation rather than an open-market purchase.
LeonaBio, Inc. director Natalie C. Holles received a grant of stock options covering 56,000 shares of common stock. The options have an exercise price of $9.63 per share and expire on May 4, 2036. The award vests in equal monthly installments over 36 months, contingent on her continued service as a Service Provider under the company’s 2026 Equity Incentive Plan. Following this grant, she holds 56,000 stock options directly.
LeonaBio, Inc. director Peter B. Silverman received a grant of stock options covering 56,000 shares of common stock. The options have an exercise price of $9.63 per share and expire on May 4, 2036. They vest monthly over 36 months, contingent on his continued service to the company.
Following this grant, Silverman holds 56,000 stock options directly, reflecting a compensation award rather than an open-market share purchase or sale.
LeonaBio, Inc. director Callori Fred received a grant of stock options covering 56,000 shares of common stock. The options have an exercise price of $9.63 per share and expire on May 4, 2036. All 56,000 options are held directly after this award.
The options are scheduled to vest in equal installments monthly over 36 months from the grant date, as long as the director continues to serve as a service provider under LeonaBio’s 2026 Equity Incentive Plan.
LeonaBio, Inc. director Michael A. Panzara received a grant of stock options covering 28,000 shares of common stock, with an exercise price of $9.54 per share and expiration on April 8, 2036. These options were granted at no upfront cost as compensation, not through an open-market purchase.
According to the grant terms, the 28,000 option shares are scheduled to vest in equal monthly installments over 24 months from the grant date, as long as Panzara continues to serve as a “Service Provider” under LeonaBio’s 2026 Equity Incentive Plan. Following this grant, he holds 28,000 derivative securities tied to LeonaBio common stock.
LeonaBio, Inc. reported that its Chief Scientific Officer, Kevin Church, received a grant of stock options covering 300,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036.
The award was received as a compensation-related grant, not an open-market purchase or sale. According to the grant terms, the options are scheduled to vest monthly over 48 months, as long as Church continues to serve as a Service Provider under LeonaBio’s 2026 Equity Incentive Plan.
LeonaBio, Inc. director Grant Pickering received a grant of stock options covering 28,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036. This is a compensation-related award, not an open-market trade.
The filing shows Pickering holding 28,000 options after the transaction. According to the footnote, the options vest monthly over 24 months from the grant date, contingent on continued service as a Service Provider under LeonaBio’s 2026 Equity Incentive Plan.
LeonaBio, Inc. director Romano Kelly A received a grant of stock options covering 28,000 shares of common stock on April 9, 2026. The options carry an exercise price of $9.54 per share and expire on April 8, 2036. According to the award terms, the 28,000 underlying shares are scheduled to vest in equal monthly installments over 24 months, contingent on Kelly continuing as a Service Provider under LeonaBio's 2026 Equity Incentive Plan.
LeonaBio, Inc. director James A. Johnson received a grant of stock options covering 28,000 shares of common stock. The options carry an exercise price of $9.54 per share and expire on April 8, 2036, and represent compensation rather than an open-market purchase.
These options are scheduled to vest monthly over 24 months on the monthly anniversaries of the grant date, as long as Johnson continues as a Service Provider under LeonaBio’s 2026 Equity Incentive Plan. Following this grant, he holds stock options for 28,000 underlying shares directly.
LeonaBio, Inc. director Joseph Edelman received a grant of stock options covering 28,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036. The award vests monthly over 24 months, so Edelman earns portions of the grant gradually as he continues to serve as a service provider. Following this grant, he holds stock options for 28,000 underlying shares directly.
LeonaBio, Inc. reported that Chief Medical Officer Javier San Martin received a grant of stock options covering 350,000 shares of common stock. The options have an exercise price of $9.54 per share, expire on April 8, 2036, and were awarded as compensation.
According to the grant terms, the options vest in equal monthly installments over 48 months from the grant date, so long as San Martin continues to serve as a Service Provider under LeonaBio's 2026 Equity Incentive Plan. This is a derivative award, not an open-market purchase or sale.
LeonaBio, Inc. reported that its General Counsel and Chief Compliance Officer, Mark Worthington, received a grant of stock options covering 300,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036.
The award was classified as a grant or other acquisition of a derivative security, with 300,000 options held directly after the transaction. According to the grant terms, the underlying shares are scheduled to vest monthly over 48 months, subject to his continued service as a provider under LeonaBio’s 2026 Equity Incentive Plan.
LeonaBio, Inc. reported that its Chief Financial Officer, Robert Renninger, received a grant of stock options covering 300,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036.
According to the grant terms, these options vest in equal monthly installments over 48 months from the grant date, contingent on Mr. Renninger continuing to serve as a service provider under LeonaBio's 2026 Equity Incentive Plan. Following this award, he holds 300,000 stock options directly.
LeonaBio, Inc. reported that President and CEO Mark James Litton received a grant of stock options for 750,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036.
These options were awarded as a compensation grant and will vest in equal monthly installments over 48 months, as long as he continues to serve as a Service Provider under LeonaBio’s 2026 Equity Incentive Plan. Following this award, he holds options covering 750,000 shares.
LeonaBio, Inc. President and CEO Mark James Litton reported several equity transactions involving company stock. On March 3, 2026, 22,254 restricted stock units were exercised at $0.00 per share, converting into the same number of common shares and bringing his direct common stock holdings to 63,082 shares.
On March 4, 2026, 5,156 common shares were sold at a weighted-average price of $5.37 per share to cover tax withholding obligations triggered by the RSU vesting under the company’s mandatory “sell to cover” policies; no additional shares were sold. After this tax-related sale, he directly owned 57,926 common shares. Separate irrevocable trusts established for his children each held 656 common shares as indirect ownership.
LeonaBio, Inc.’s chief financial officer reported routine equity activity involving restricted stock units and a small tax-related sale. On March 3, 3,900 restricted stock units vested and converted into the same number of common shares. On March 4, 906 common shares were sold at a weighted-average price of $5.37 solely to cover tax withholding obligations under a mandatory “sell to cover” policy, leaving 15,851 common shares held directly.
LeonaBio, Inc. executive Mark Worthington reported a mix of share transactions tied to vesting equity awards. On March 3, 2026, 5,726 restricted stock units were exercised into the same number of common shares at $0.00 per share, reflecting a standard RSU conversion.
On March 4, 2026, 1,328 common shares were sold in an open-market transaction at a weighted-average price of $5.37 per share to cover tax withholding obligations under LeonaBio’s mandatory “sell to cover” policies, which the filing notes was not a discretionary sale. After these transactions, Worthington directly held 18,376 common shares.
LeonaBio, Inc. Chief Scientific Officer Kevin Church reported RSU vesting and related share transactions. On March 3, he exercised 5,856 restricted stock units, each converting into one share of common stock at a stated price of $0.00 per share.
Those RSUs, originally granted as 5,856 units on March 3, 2025 and vesting in full one year later, increased his common stock holdings. On March 4, 1,359 common shares were sold in open-market transactions at a weighted-average price of $5.37 per share solely to cover tax withholding obligations under LeonaBio’s mandatory “sell to cover” policy.
After these transactions, Church directly held 25,178 shares of LeonaBio common stock.
LeonaBio, Inc.’s chief medical officer Javier San Martin reported equity compensation activity and a related tax sale. On March 3, 2026, 7,418 restricted stock units (RSUs) fully vested and were converted into 7,418 shares of common stock at a stated price of $0.00 per share.
On March 4, 2026, 1,720 shares of common stock were sold in open-market transactions at a weighted-average price of $5.37 per share, solely to cover tax withholding obligations under LeonaBio’s mandatory “sell to cover” policies, and not as a discretionary sale. After these transactions, Javier San Martin directly owned 15,887 shares of LeonaBio common stock.